Agonal respiration

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

Retrieved on: 
수요일, 5월 1, 2024
Conditional sentence, Brain, Drug, Enzyme, Patient, Bone marrow, Acetone, Organelle, Soybean, Inflammation, Methane, Protein, Cell, Laboratory, Mineral, Pregnancy, Blood, Yolk, Health, Apoptosis, Human body, Death, Research, Vitamin, Water, Carbon, Functional food, Phospholipid, Kaifeng, Dietary fiber, Disease, Convalescence, Agonal respiration, Human, Mitochondrion, SISI, Food, Medicine, PC, Golgi, Carbohydrate, Nutrient, Beauty, Signal transduction, Temperature, Ageing, Microsome, Lipid, Cell damage, Malabsorption, Growth, Fats, Phosphorus

Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.

Key Points: 
  • Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
  • Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
  • When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
  • The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.

Valbiotis publishes its annual accounts 2023

Retrieved on: 
금요일, 5월 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
화요일, 4월 9, 2024
Lung, TUSC2, Agonal respiration, Metabolism, Gene, Apoptosis, Cell, NSCLC, Nanoparticle, Patient, Neoplasm, Research, Pembrolizumab, Date, NPRL2, Lung cancer, Immunity, ATP, ALK, Glycolysis

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

Orphan designation: Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter Treatment of Duchenne muscular dystrophy, 14/10/2016 Positive

Retrieved on: 
화요일, 4월 9, 2024
Eurostat, Civil service commission, Wasting, Diagnosis, Atrophy, Mutation, B cell, Weakness, Disease, Agonal respiration, Patient, Committee, Knowledge, Regulation, EMA, IRIS, Death, Human, Duchenne muscular dystrophy, Dystrophin, European, COMP, Heart, Safety, European Commission, Muscle weakness, Marketing, DMD, DSM-IV codes, Medicine, Pharmaceutical industry

Orphan designation: Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter Treatment of Duchenne muscular dystrophy, 14/10/2016 Positive

Key Points: 


Orphan designation: Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter Treatment of Duchenne muscular dystrophy, 14/10/2016 Positive

Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Retrieved on: 
화요일, 4월 9, 2024
Community, Eurostat, Civil service commission, Diagnosis, U1 spliceosomal RNA, Capsid, Gene, B cell, Cell, Disease, Agonal respiration, Patient, Committee, Knowledge, Regulation, EMA, IRIS, Protein, Human, Duchenne muscular dystrophy, Dystrophin, European, COMP, Heart, European Commission, Safety, Muscle weakness, Blood, DMD, DSM-IV codes, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Key Points: 


Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
월요일, 3월 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

Innovation In Every Sip: Nokix's Quest For The Ultimate Flavor & Wellness Experience

Retrieved on: 
금요일, 3월 22, 2024
Agonal respiration, Health, Pantothenic acid, Vitamin, Taste, Vitamin A, Carbohydrate, Vitamin D, Skin, Vitamin B6, Water, Movement, Vitamin B12, Bottled water

SACRAMENTO, Calif., March 22, 2024 /PRNewswire/ -- Nokix Sparkling Water is redefining the beverage industry with its innovative approach to crafting the ultimate flavor experience.

Key Points: 
  • SACRAMENTO, Calif., March 22, 2024 /PRNewswire/ -- Nokix Sparkling Water is redefining the beverage industry with its innovative approach to crafting the ultimate flavor experience.
  • Each sip embodies the spirit of innovation, offering a healthier, flavorful alternative in the market.
  • Experience the innovative blend of flavors and the commitment to quality with every sip of Nokix Sparkling Water.
  • Sign up for exclusive updates and be part of our journey towards launching the ultimate flavor experience at www.nokixsparkling.com .

What is metabolism? A biochemist explains how different people convert energy differently − and why that matters for your health

Retrieved on: 
금요일, 4월 5, 2024
Blood pressure, Agonal respiration, Dicarboxylic acid, Kynurenine, Health, Metabolism, Burn, COVID, Obesity, Sport, Exercise, Cell, Multiple sclerosis, Diabetes, COVID-19, Patient, Inflammation, Social media, Mitochondrion, Fats, Electron, Radiation exposure, Food, Carbohydrate, Smoke, Anti-transglutaminase antibodies, Medicine, Protein, Athlete, Carbon, Coenzyme A, Phenotype, Oxygen, Metabolic syndrome, BMI, Blood, Ageing, Medical device

But what exactly is your metabolism?

Key Points: 
  • But what exactly is your metabolism?
  • Everything you expose your body to – from lifestyle to an airborne virus – influences your physical characteristics, such as your blood pressure and energy levels.

Metabolism is energy conversion

  • At the chemical level, energy metabolism begins when the three macronutrients – carbohydrates, fats and protein – are broken down atom by atom to release electrons from chemical bonds.
  • Simply put, a primary role of metabolism is to convert chemical energy into electrical energy and back into chemical energy.
  • I am a biochemist who studies the various networks of metabolism that are used as your body changes.
  • My team and I have been able to define specific traits of metabolism, such as the presence and amount of certain metabolites – products made from breaking down macronutrients – across a wide range of conditions.

Elite athletes define the upper limits

  • Elite athletes offer a prime population to study metabolic function at its best, since their network of molecular and chemical reactions must be finely tuned to compete on the world stage.
  • Traditionally, lactate threshold has been a critical measure of athletic performance by pinpointing exercise intensity when lactate starts to rise in muscles and blood.
  • When comparing the lactate thresholds of a group of elite cyclists, we found that the cyclists with higher thresholds had markers of better mitochondrial function.

Dysfunctional metabolism in diseases like COVID-19

  • Your metabolism also changes if you get an acute illness such as COVID-19.
  • In contrast to elite cyclists, COVID-19 patients have an impaired ability to burn fat that appears to persist with long COVID.


Burning fat uses a lot of oxygen. COVID-19 damages the red blood cells that deliver oxygen to organs. Because red blood cells have a limited ability to repair themselves, they might not function as well during the remainder of their roughly 120-day life span. This may partially explain why COVID symptoms last as long as they do in some people.

Blood donors define the middle

  • Blood donors, coming from every walk of life, also have a diverse range of biological traits as a study population.
  • My team and I looked at blood from over 13,000 blood donors to shed light on their metabolic diversity.
  • We found that blood from donors with higher levels of kynurenine was less likely to restore hemoglobin levels in transfusion recipients compared with donors with lower kynurenine levels.


In addition to his appointment at the University of Colorado, Travis Nemkov is an Affiliate Investigator of Vitalant Research Institute and a co-founder of Omix Technologies.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
수요일, 3월 6, 2024
Glioblastoma, NSCLC, Diabetes, Lung, Lung cancer, Metabolism, EGFR, Osteosarcoma, MD, Neoplasm, FDA, Cancer, Glycolysis, Food, Growth, Anaplastic lymphoma kinase, Pembrolizumab, AACR, Cell, Apoptosis, Date, Osimertinib, Agonal respiration, Mitochondrion, Breast, University, Nanoparticle, Food and Drug Administration, NPRL2, Patient, ATP, Clinical trial, Gene, Disease, TUSC2, Trial of the century, Mesothelioma, Research, ALK, Vaccine

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis

Retrieved on: 
금요일, 1월 26, 2024
Principal, ALS, Research, University of Tokushima, Biomedical sciences, Patient, Safety, Respiratory failure, Ministry, Neurodegenerative disease, Paralysis, Disease, MHLW, JAMA Neurology, Agonal respiration, Death, Eisai, Medication, PDMA, Muscle atrophy, NDA, Pharmaceutical industry

TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.

Key Points: 
  • TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
  • In May 2022, ultrahigh-dose mecobalamin received orphan drug designation by the Ministry of Health, Labour and Welfare (MHLW).
  • The results of JETALS were published in the peer-reviewed journal JAMA Neurology.
  • ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction.